Mirabel: an integrated project for risk and cost/benefit analysis of peanut allergy

Food allergy is a major public health issue. However, no regulatory measures exist when allergens are present at trace levels and the different risk components are poorly described. Thus, knowledge on exposure components such as the allergens present in foods and the consumption behaviour of allergic consumers and models to estimate the related risk need to be enriched. Mirabel proposes for the first time studying each risk component using an integrated approach in order to improve the quality of life of the allergic population. Field surveys were conducted in order to fill in the current gaps in unintentional allergen traces in food, allergic consumers' food behaviour, threshold doses of allergic reaction, allergy symptoms and severity. The aim is also to propose methodological and operational tools to quantify allergic risk, to test management scenarios and to produce a cost/benefit analysis. Medical data on the peanut allergies of 785 patients were collected in the MIRABEL survey and 443 patients answered the food consumption questionnaire. The population surveyed was mostly paediatric - 86% were children under 16 years of age, with a high percentage of males (60%). This project will generate tangible results on peanut allergen exposure and risk which could be used in future risk assessment work and particularly to provide science-based guidance to set up concentration limits for peanut traces on packages; L'allergie alimentaire est un enjeu majeur de santé publique. Ce texte présente en détail le protocole Mirabel concernant l’allergie à l’arachide. L'objectif de ce projet est de proposer des outils méthodologiques et opérationnels pour quantifier le risque allergique, pour tester des scénarios de gestion, et de produire une analyse coût / bénéfice concernant ces scénarios de gestion visant à réduire le risque. Les analyses à venir seront réalisées à partir des données médicales de 785 patients et des habitudes de consommation alimentaires de 443 patients.